Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Executive Summary
Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.
You may also be interested in...
Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm
Teva’s planned divestment of non-core assets in order to refocus the company after a troubled first-half has started with a contraceptive device.
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.